Brief: Plx Pharma Submits Supplemental New Drug Applications For Vazalore To U.S. FDA
16/11/2020 22:27
Nov 16 (Reuters) - PLx Pharma Inc PLXP.O :
* PLX PHARMA INC. SUBMITS SUPPLEMENTAL NEW DRUG APPLICATIONS
FOR
VAZALORE™ 325 MG AND 81 MG TO U.S. FOOD AND DRUG ADMINISTRATION
* PLX PHARMA INC - TARGETING LAUNCH OF VAZALORE FOR Q3 2021
Source text for Eikon: ID:nGNX4xtHJh
Further company coverage: PLXP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PLx Pharma Winddown
See all newsAustralia's Pilbara Minerals jumps on Pilgangoora lithium resource upgrade
Brief: Plx Pharma Winddown Terminated Employment Of Natasha Giordano, President And CEO, And Rita O'connor, CFO
Brief: PLx Pharma Inc. Enters Into A Stalking Horse Asset Purchase Agreement To Sell Vazalore And Substantially All Of Its Assets
U.S. STOCKS ON THE MOVE-HeartCore, Freight Technologies, MongoDB
Brief: Plx Pharma Inc. Receives Nasdaq Delisting Notice